Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOX6EJ)

Drug Name

PF-06840003 Drug Info

Synonyms

3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione; 198474-05-4; PF06840003; 2,5-Pyrrolidinedione, 3-(5-fluoro-1H-indol-3-yl)-; 3-(5-fluoro-indol-3-yl)-pyrrolidine-2,5-dione; SCHEMBL5463464; GTPL9565; CTK0A0183; DTXSID00630149; MXKLDYKORJEOPR-UHFFFAOYSA-N; KS-000008MY; EX-A1186; EOS200271; AKOS027252536; CS-6186; AS-51973; HY-101111; 3-(5-Fluoro-1H-indol-3-yl)-pyrrolidine-2,5-dione

Indication

Disease Entry	ICD 11	Status	REF
Glioma	2A00.0	Phase 1	[1]

Cross-matching ID

PubChem CID: 23063810
CAS Number: CAS 198474-05-4
TTD Drug ID: DMOX6EJ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Indoleamine 2,3-dioxygenase 1 (IDO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-Tryptophan	DMIBH7M	Depression	6A70-6A7Z	Approved	[2]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[3]
BMS-986205	DM3MAYQ	Melanoma	2C30	Phase 3	[4]
INCB24360	DMIJGT9	Urothelial carcinoma	2C92.0	Phase 3	[5]
NLG8189	DM0798Z	Melanoma	2C30	Phase 2/3	[4]
DN1406131	DMQFX8R	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
HTI-1090	DMI4TEC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
KHK2455	DMLSUQ8	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
LY3381916	DMONZ1L	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
NLG802	DMP9J5V	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Indoleamine 2,3-dioxygenase 1 (IDO1)	TTZJYKH	I23O1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry. 2006 Jul 18;45(28):8527-38.
3	Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Incyte. Product Development Pipeline.
6	ClinicalTrials.gov (NCT03641794) Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers. U.S. National Institutes of Health.
7	Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation. J Enzyme Inhib Med Chem. 2019 Dec;34(1):250-263.